Market Research Industry Reports

Keloids - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Keloids - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H2 2017, provides an overview of the Keloids (Dermatology) pipeline landscape.

Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Keloids - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Keloids (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Keloids (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Keloids (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keloids (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keloids (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keloids (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keloids (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Keloids - Overview
Keloids - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Keloids - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Keloids - Companies Involved in Therapeutics Development
FirstString Research Inc
RXi Pharmaceuticals Corp
Topadur Pharma AG
Tumorend LLC
viDA Therapeutics Inc
Yuhan Corp
Keloids - Drug Profiles
CM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
koebnerisin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
psoriasin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOPN-44 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
V-2248 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTI-3000 Series - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-siRNA1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Keloids - Dormant Projects
Keloids - Discontinued Products
Keloids - Product Development Milestones
Featured News & Press Releases
Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109
Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Keloids, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Keloids - Pipeline by FirstString Research Inc, H2 2017
Keloids - Pipeline by RXi Pharmaceuticals Corp, H2 2017
Keloids - Pipeline by Topadur Pharma AG, H2 2017
Keloids - Pipeline by Tumorend LLC, H2 2017
Keloids - Pipeline by viDA Therapeutics Inc, H2 2017
Keloids - Pipeline by Yuhan Corp, H2 2017
Keloids - Dormant Projects, H2 2017
Keloids - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Keloids, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Keloids - Pipeline Review, H1 2018

Keloids - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H1 2018, provides an overview of the Keloids (Dermatology) pipeline landscape.Keloids

USD 2000View Report

Keloids - Pipeline Review, H2 2017

Keloids - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H2 2017, provides an overview of the Keloids (Dermatology) pipeline landscape.Keloids

USD 2000View Report

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H1 2018

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) -

USD 3500View Report

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H1 2018

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H1 2018According to the recently published report Tryptophan

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Dec 2017
No. of Pages :46
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube